2015•Supportive Care in CancerRequires access

Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial

Sameer Bakhshi, Atul Batra, Bivas Biswas, Deepa Dhawan, Reeja Paul, Vishnubhatla Sreenivas

Open publisher page 55 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 55 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Aprepitant, Medicine, Ondansetron, Vomiting, Placebo, Antiemetic, Chemotherapy, NK1 receptor antagonist

Back to paper search Browse research topics Original source

Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial — Research Paper | ScholarLens